Top Growth Companies With Strong Insider Ownership November 2024

In the midst of a busy earnings season, global markets have experienced volatility with major indices generally finishing lower, as growth stocks lagged behind value shares. Despite these fluctuations, companies with high insider ownership often signal strong confidence from those closest to the business, making them compelling considerations for investors seeking stability and potential growth in uncertain times.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)

17.3%

21.1%

Archean Chemical Industries (NSEI:ACI)

22.9%

34%

Kirloskar Pneumatic (BSE:505283)

30.3%

26.3%

People & Technology (KOSDAQ:A137400)

16.4%

35.6%

Laopu Gold (SEHK:6181)

36.4%

33%

Alkami Technology (NasdaqGS:ALKT)

11.2%

98.6%

Adveritas (ASX:AV1)

21.2%

144.2%

Plenti Group (ASX:PLT)

12.8%

107.6%

EHang Holdings (NasdaqGM:EH)

32.8%

81.4%

UTI (KOSDAQ:A179900)

33.1%

134.6%

Click here to see the full list of 1538 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Raytron TechnologyLtd

Simply Wall St Growth Rating: ★★★★★☆

Overview: Raytron Technology Co., Ltd. specializes in the R&D, design, manufacturing, and sales of uncooled infrared imaging and MEMS sensor technology in China, with a market cap of CN¥21.62 billion.

Operations: Raytron Technology Co., Ltd. generates its revenue primarily from the development and sale of uncooled infrared imaging and MEMS sensor technology in China.

Insider Ownership: 26.8%

Raytron Technology Ltd. has shown strong growth with earnings increasing by 14.4% over the past year and revenue forecasted to grow at 21.8% annually, outpacing the market average. Recent earnings reports indicate a rise in net income to CNY 483.4 million for the first nine months of 2024, up from CNY 386.89 million last year. The company is trading at a favorable price-to-earnings ratio of 36.5x compared to industry peers, despite recent share price volatility and completed buybacks totaling CNY 49.43 million.

SHSE:688002 Earnings and Revenue Growth as at Nov 2024
SHSE:688002 Earnings and Revenue Growth as at Nov 2024

Suzhou Zelgen BiopharmaceuticalsLtd

Simply Wall St Growth Rating: ★★★★★☆

Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a company focused on the development and commercialization of innovative biopharmaceutical products, with a market cap of CN¥16.66 billion.

Operations: The company's revenue is primarily generated from its pharmaceuticals segment, amounting to CN¥488.45 million.